share_log

424B5: Prospectus

424B5: Prospectus

424B5：募資說明書
美股sec公告 ·  07/27 01:23
牛牛AI助理已提取核心訊息
60 Degrees Pharmaceuticals, Inc., listed on The Nasdaq Capital Market under the symbol 'SXTP', has announced an increase in the maximum aggregate gross sales price of its common stock to $2,190,416 through an At the Market Issuance Sales Agreement with WallachBeth Capital LLC. This increase, detailed in a prospectus supplement filed on July 26, 2024, amends previous registrations to allow for additional sales under the agreement. As of the filing date, 60 Degrees Pharmaceuticals has sold 7,525,879 shares for an aggregate gross sales price of $1,890,500.81. The company's outstanding common stock held by non-affiliates is valued at approximately $6,571,249, based on a share price of $0.351 as of June 7, 2024. The company adheres to the SEC's General Instruction I.B.6 of Form S-3, limiting sales to no more than one-third of their public float in a 12-month period, provided the public float remains below $75 million. Investors are advised to consider the risk factors outlined in the accompanying prospectus supplement and base prospectus, as well as other SEC filings.
60 Degrees Pharmaceuticals, Inc., listed on The Nasdaq Capital Market under the symbol 'SXTP', has announced an increase in the maximum aggregate gross sales price of its common stock to $2,190,416 through an At the Market Issuance Sales Agreement with WallachBeth Capital LLC. This increase, detailed in a prospectus supplement filed on July 26, 2024, amends previous registrations to allow for additional sales under the agreement. As of the filing date, 60 Degrees Pharmaceuticals has sold 7,525,879 shares for an aggregate gross sales price of $1,890,500.81. The company's outstanding common stock held by non-affiliates is valued at approximately $6,571,249, based on a share price of $0.351 as of June 7, 2024. The company adheres to the SEC's General Instruction I.B.6 of Form S-3, limiting sales to no more than one-third of their public float in a 12-month period, provided the public float remains below $75 million. Investors are advised to consider the risk factors outlined in the accompanying prospectus supplement and base prospectus, as well as other SEC filings.
60 Degrees Pharmaceuticals, Inc.位於納斯達克資本市場，股票代號爲“SXTP”，宣佈通過與WallachBeth Capital LLC簽訂的現場發行銷售協議，將其普通股的最大總銷售價格提高到$2,190,416。此次增加於2024年7月26日提交的招股書補充描述中，修訂了先前的註冊以允許在協議下進行額外的銷售。截至提交日期，60 Degrees Pharmaceuticals已經以$1,890,500.81的總銷售價格出售了7,525,879股股票。根據2024年6月7日每股$0.351的股價，公司持有的非關聯方普通股市值約爲$6,571,249。根據公司遵守SEC的S-3表格的一般規定I.b.6的規定，在12個月內限制銷售量不超過其公共浮動股份的三分之一，前提是公共浮動股份保持在7500萬美元以下。投資者應考慮到伴隨的招股書補充及基礎招股書中提到的風險因素，以及其他的SEC文件。
60 Degrees Pharmaceuticals, Inc.位於納斯達克資本市場，股票代號爲“SXTP”，宣佈通過與WallachBeth Capital LLC簽訂的現場發行銷售協議，將其普通股的最大總銷售價格提高到$2,190,416。此次增加於2024年7月26日提交的招股書補充描述中，修訂了先前的註冊以允許在協議下進行額外的銷售。截至提交日期，60 Degrees Pharmaceuticals已經以$1,890,500.81的總銷售價格出售了7,525,879股股票。根據2024年6月7日每股$0.351的股價，公司持有的非關聯方普通股市值約爲$6,571,249。根據公司遵守SEC的S-3表格的一般規定I.b.6的規定，在12個月內限制銷售量不超過其公共浮動股份的三分之一，前提是公共浮動股份保持在7500萬美元以下。投資者應考慮到伴隨的招股書補充及基礎招股書中提到的風險因素，以及其他的SEC文件。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。